Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis

Rheumatology International

Volumn 30, Issue 6, 2010, Pages 725-730

  Ichikawa, Tetsuya ^a   Kageyama, Yasunori ^b   Kobayashi, Hayato ^b   Kato, Norihiko ^b   Tsujimura, Kunio ^c   Koide, Yukio ^c  

^a Narita Memorial Hospital   (Japan)

^b Fujieda Heisei Memorial Hospital   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Etanercept; Growth regulated protein alpha; Interferon gamma inducible protein 10; Interleukin 15; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE; ETANERCEPT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH REGULATED PROTEIN ALPHA; INTERLEUKIN 15; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

AGED; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CHEMOKINE CXCL1; CHEMOKINE CXCL10; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-15; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951023893     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1356-y     Document Type: Article

References (40)

1. Arend WP, Dayer J-M (1995) Inhibition of the production and eVects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38:151-160
2. Maini RN, Taylor PC (2000) Anti-cytokine therapy for rheumatoid arthritis. Ann Rev Med 51:207-229
3. Woo CH, Kim TH, Choi JA, Ryu HC, Lee JE, You HJ et al (2006) Inhibition of receptor internalization attenuates the TNF alpha-induced ROS generation in non-phagocytic cells. Biochem Biophys Res Commun 351:972-978
4. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y et al (2003) NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 22:3898-3909
5. Kageyama Y, Takahashi M, Torikai E, Suzuki M, Ichikawa T, Nagafusa T et al (2007) Treatment with anti-TNF-alpha antibody inXiximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 26:505-509 (Pubitemid 46359288)
6. Torikai E, Kageyama Y, Suzuki M, Ichikawa T, Nagano A (2007) The eVect of inXiximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol 26:1088-1093
7. Kageyama Y, Torikai E, Nagano A (2007) Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int 27:467-472 (Pubitemid 46294986)
8. Neville LF, Mathiak G, Bagasra O (1997) The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8:207-219
9. Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y et al (2003) A novel mechanism for the regulation of IFNgamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 5:74-81
10. Berthier-Vergnes O, Bermond F, Flacher V, Massacrier C, Schmitt D, Péguet-Navarro J (2005) TNF-alpha enhances phenotypic and functional maturation of human epidermal Langerhans cells and induces IL-12 p40 and IP-10/CXCL-10 production. FEBS Lett 579:60-68
11. Thorburn E, Kolesar L, Brabcova E, Petrickova K, Petricek M, Jaresova M et al (2009) CXC and CC chemokines induced in human renal epithelial cells by inXammatory cytokines. APMIS 117:477-487
12. Boorsma DM, De Haan P, Willemze R, Stoof TJ (1994) Human growth factor (huGRO), interleukin-8 (IL-8) and interferon-gamma- inducible protein (gamma-IP-10) gene expression in cultured normal human keratinocytes. Arch Dermatol Res 286:471-475
13. Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, Miyazaki S et al (1999) A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol 162:2754-2760
14. König A, Krenn V, Toksoy A, Gerhard N, Gillitzer R (2000) Mig, GRO alpha and RANTES messenger RNA expression in lining layer, inWltrates and diVerent leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Virchows Arch 436:449-458
15. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN (1997) EVect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 57:117-120
16. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J (2004) EVect of repeated inXiximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 31:238-242
17. Zhang HG, Hyde K, Page GP, Brand JP, Zhou J, Yu S et al (2004) Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. Arthritis Rheum 50:420-431
18. Zoja C, Wang JM, Bettoni S, Sironi M, Renzi D, ChiaVarino F et al (1991) Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. Am J Pathol 138:991-1003
19. Visser CE, Tekstra J, Brouwer-Steenbergen JJ, Tuk CW, Boorsma DM, Sampat-Sardjoepersad SC et al (1998) Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES. Clin Exp Immunol 112:270-275
20. Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S (1993) Monocyte chemoattractant protein-1 (MCP-1) in inXammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 69:83-91
21. Arend WP, Dayer JM (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305-315
22. Harada S, Yamamura M, Okamoto H, Morita Y, Kawashima M, Aita T, Makino H (1999) Production of interleukin-7 and interleukin- 15 by Wbroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 42:1508-1516
23. Miranda-Carus ME, Balsa A, Benito-Miguel M, Perez De Ayala C, Martin-Mola E (2004) IL-15 and the initiation of cell contactdependent synovial Wbroblast-T lymphocyte cross-talk in rheumatoid arthritis: eVect of methotrexate. J Immunol 173:1463-1476
24. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN et al (2005) Early rheumatoid arthritis is characterized by a distinct and transient synovial Xuid cytokine proWle of T cell and stromal cell origin. Arthritis Res Ther 7:784-795
25. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY (1998) Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen- induced immunopathology. J Immunol 160:5654-5660
26. Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, Zheng XX et al (2004) Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 173:5818-5826
27. Ernestam S, Klint E, Catrina AI, Sundberg E, Engström M, Klareskog L, Ulfgren AK (2006) Synovial expression of IL-15 in rheumatoid arthritis is not inXuenced by blockade of tumour necrosis factor. Arthritis Res Ther 8:R18
28. Bédard PA, Golds EE (1993) Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and Wbroblasts. Cell Physiol 154:433-441
29. Boorsma DM, Flier J, Sampat S, Ottevanger C, De Haan P, Hooft L et al (1998) Chemokine IP-10 expression in cultured human keratinocytes. Arch Dermatol Res 290:335-341
30. Cassatella MA, Gasperini S, Calzetti F, Bertagnin A, Luster AD, McDonald PP (1997) Regulated production of the interferon-gamma- inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol 27:111-115
31. Ebnet K, Simon MM, Shaw S (1996) Regulation of chemokine gene expression in human endothelial cells by proinXammatory cytokines and Borrelia burgdorferi. Ann N Y Acad Sci 797:107-117
32. Luster AD, Unkeless JC, Ravetch JV (1985) Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672-676
33. Luster AD (1998) Chemokines-chemotactic cytokines that mediate inXammation. N Engl J Med 338:436-445
34. Luster AD, Ravetch JV (1987) Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 166:1084-1097
35. Neville LF, Mathiak G, Bagasra O (1997) The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8:207-219
36. Kwak HB, Ha H, Kim HN, Lee JH, Kim HS, Lee S et al (1997) Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 58:1332-1342
37. Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y et al (2003) A novel mechanism for the regulation of IFNgamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 5:74-81
38. Patel DD, Zachariah JP, Whichard LP (2001) CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 98:39-45
39. Rigby WF (2007) Drug insight: diVerent mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 3:227-233
40. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y et al (2005) InXiximab induces potent anti-inXammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 128:376-392